This research aims to evaluate the efficacy and safety of mirogabalin combined with opioids compared to opioids alone in treating neuropathic cancer pain.
Conducted as a clinical trial in Japan
Compared two treatment groups: mirogabalin + opioids vs. opioids alone
Measured efficacy and safety outcomes in neuropathic cancer pain patients
Mirogabalin combined with opioids showed improved pain relief compared to opioids alone
Safety profiles were similar in both treatment groups
Data indicate a significant reduction in neuropathic pain using the combination therapy
Resumen
Japan Registry of Clinical Trials (https://jrct.mhlw.go.jp/) identifier is jRCTs031220569.
Preguntar a la IA
Me gusta
Guardar
Compartir
Ver artículo completo
Preguntar a la IA
Me gusta
Guardar
Compartir
Ver artículo completo
Efficacy and safety of mirogabalin + opioids vs opioids alone for neuropathic cancer pain: Miro-Canp | Synapse